mAb-话题@MedSci

#mAb#

1302篇内容 | 2888人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1912530, encodeId=d85e1912530ba, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lenzilumab治疗COVID-19住院患者，即将开展III期临床, objectType=article, longId=206522, objectId=76e2206522a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76e2206522a7, replyNumber=0, likeNumber=59, createdTime=2021-06-13, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76e2206522a7, moduleTitle=Lenzilumab治疗COVID-19住院患者，即将开展III期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76e2206522a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912473, encodeId=8ce119124e32c, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA顾问小组不支持阿尔茨海默氏病药物aducanumab, objectType=article, longId=203070, objectId=21562030e0d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21562030e0d8, replyNumber=0, likeNumber=68, createdTime=2021-02-05, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21562030e0d8, moduleTitle=FDA顾问小组不支持阿尔茨海默氏病药物aducanumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21562030e0d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912433, encodeId=f2d319124332b, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次, objectType=article, longId=199785, objectId=1282199e85f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1282199e85f7, replyNumber=0, likeNumber=92, createdTime=2021-04-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1282199e85f7, moduleTitle=FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1282199e85f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912499, encodeId=8f4d19124997d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：Evinacumab 治疗难治性高胆固醇血症, objectType=article, longId=204386, objectId=6349204386b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6349204386b7, replyNumber=0, likeNumber=68, createdTime=2021-10-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6349204386b7, moduleTitle=NEJM：Evinacumab 治疗难治性高胆固醇血症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6349204386b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912550, encodeId=3c5a19125506f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, objectType=article, longId=207517, objectId=3e5020e5170d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e5020e5170d, replyNumber=0, likeNumber=72, createdTime=2021-05-27, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e5020e5170d, moduleTitle=Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e5020e5170d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912572, encodeId=c37f19125e2e8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, objectType=article, longId=208916, objectId=dc73208916ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc73208916ac, replyNumber=0, likeNumber=64, createdTime=2021-07-10, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc73208916ac, moduleTitle=J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc73208916ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912384, encodeId=414f191238425, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=68, createdTime=2021-02-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912416, encodeId=9ca619124162e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Int J Clin Oncol：PembrolizumabVS化疗治疗复发性晚期尿道癌的疗效, objectType=article, longId=198492, objectId=2b63198492b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b63198492b1, replyNumber=0, likeNumber=66, createdTime=2021-04-16, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b63198492b1, moduleTitle=Int J Clin Oncol：PembrolizumabVS化疗治疗复发性晚期尿道癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b63198492b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912397, encodeId=7cc1191239e10, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用, objectType=article, longId=197251, objectId=93ea19e25141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93ea19e25141, replyNumber=0, likeNumber=61, createdTime=2021-01-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93ea19e25141, moduleTitle=Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93ea19e25141)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912495, encodeId=d6c51912495f4, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, objectType=article, longId=203864, objectId=69b5203864d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69b5203864d9, replyNumber=0, likeNumber=76, createdTime=2021-03-09, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69b5203864d9, moduleTitle=NICE拒绝了诺华的Adakveo（crizanlizumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69b5203864d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912411, encodeId=6659191241159, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Ann Rheum Dis：重症新冠肺炎炎症风暴使用sarilumab阻断白介素-6的疗效, objectType=article, longId=197867, objectId=26d719e867cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26d719e867cc, replyNumber=0, likeNumber=0, createdTime=2021-02-23, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26d719e867cc, moduleTitle=Ann Rheum Dis：重症新冠肺炎炎症风暴使用sarilumab阻断白介素-6的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26d719e867cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912437, encodeId=1559191243e3f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=类风湿关节炎药物Kevzara（sarilumab）无法治疗COVID-19, objectType=article, longId=200396, objectId=76c22003960a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76c22003960a, replyNumber=0, likeNumber=59, createdTime=2021-06-01, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76c22003960a, moduleTitle=类风湿关节炎药物Kevzara（sarilumab）无法治疗COVID-19, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76c22003960a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912583, encodeId=b33119125834e, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=NEJM：sutimlimab治疗冷凝集素病效果喜人, objectType=article, longId=209764, objectId=97d6209e6430, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97d6209e6430, replyNumber=0, likeNumber=76, createdTime=2021-10-04, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97d6209e6430, moduleTitle=NEJM：sutimlimab治疗冷凝集素病效果喜人, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97d6209e6430)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912380, encodeId=c2201912380a8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元, objectType=article, longId=195642, objectId=43db195642e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43db195642e7, replyNumber=0, likeNumber=63, createdTime=2021-03-07, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43db195642e7, moduleTitle=合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43db195642e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912528, encodeId=8c11191252898, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者, objectType=article, longId=206511, objectId=cbe82065113c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cbe82065113c, replyNumber=0, likeNumber=52, createdTime=2022-01-03, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cbe82065113c, moduleTitle=WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cbe82065113c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912389, encodeId=9aff1912389f6, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=Lancet Rheumato：Mavrilimumab可改善重症COVID-19肺炎临床结果, objectType=article, longId=196061, objectId=c9b91960614a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c9b91960614a, replyNumber=0, likeNumber=61, createdTime=2021-04-15, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c9b91960614a, moduleTitle=Lancet Rheumato：Mavrilimumab可改善重症COVID-19肺炎临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c9b91960614a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912424, encodeId=c2ee1912424c0, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=etrolizumab治疗溃疡性结肠炎：III期结果并不乐观, objectType=article, longId=199178, objectId=e1f71991e85b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1f71991e85b, replyNumber=0, likeNumber=71, createdTime=2020-09-08, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1f71991e85b, moduleTitle=etrolizumab治疗溃疡性结肠炎：III期结果并不乐观, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1f71991e85b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912364, encodeId=562e19123648d, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, objectType=article, longId=194315, objectId=4a69194315ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a69194315ed, replyNumber=0, likeNumber=85, createdTime=2021-03-19, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a69194315ed, moduleTitle=ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a69194315ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912408, encodeId=e5fe191240895, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）, objectType=article, longId=197593, objectId=979d19e59394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=979d19e59394, replyNumber=0, likeNumber=82, createdTime=2020-10-24, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=979d19e59394, moduleTitle=FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=979d19e59394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1912383, encodeId=7b5c1912383d8, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, objectTitle=欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎, objectType=article, longId=195833, objectId=7404195833c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7404195833c3, replyNumber=0, likeNumber=88, createdTime=2021-04-22, rootId=0, userName=snf701207, userId=25e7304, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7404195833c3, moduleTitle=欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7404195833c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

mAb

2020-05-29

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lenzilumab治疗COVID-19住院患者，即将开展III期临床

2021-06-13

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA顾问小组不支持阿尔茨海默氏病药物aducanumab

2021-02-05

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA批准也是**一个多发性硬化症患者自行注射的B细胞疗法Kesimpta（ofatumumab），只需每月注射一次

2021-04-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：Evinacumab 治疗难治性高胆固醇血症

2021-10-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Haematol：依鲁替尼加用Ublituximab可显著提高复发性/难治性慢性淋巴细胞白血病患者的缓解率

2021-05-27

snf701207 (审核中...)

前往app查看评论内容

#mAb#

J Immunother Cancer：Camrelizumab联合阿帕替尼治疗晚期肝癌的效果

2021-07-10

snf701207 (审核中...)

前往app查看评论内容

#mAb#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2021-02-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Int J Clin Oncol：PembrolizumabVS化疗治疗复发性晚期尿道癌的疗效

2021-04-16

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Cancer Sci：Pembrolizumab单抗治疗在日本晚期卵巢癌患者中的应用

2021-01-22

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NICE拒绝了诺华的Adakveo（crizanlizumab）

2021-03-09

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Ann Rheum Dis：重症新冠肺炎炎症风暴使用sarilumab阻断白介素-6的疗效

2021-02-23

snf701207 (审核中...)

前往app查看评论内容

#mAb#

类风湿关节炎药物Kevzara（sarilumab）无法治疗COVID-19

2021-06-01

snf701207 (审核中...)

前往app查看评论内容

#mAb#

NEJM：sutimlimab治疗冷凝集素病效果喜人

2021-10-04

snf701207 (审核中...)

前往app查看评论内容

#mAb#

合作开发双特异性抗体！艾伯维向Genmab预付款高达7.5亿美元

2021-03-07

snf701207 (审核中...)

前往app查看评论内容

#mAb#

WCLC 2020：Patritumab Deruxtecan治疗EGFR突变的NSCLC患者

2022-01-03

snf701207 (审核中...)

前往app查看评论内容

#mAb#

Lancet Rheumato：Mavrilimumab可改善重症COVID-19肺炎临床结果

2021-04-15

snf701207 (审核中...)

前往app查看评论内容

#mAb#

etrolizumab治疗溃疡性结肠炎：III期结果并不乐观

2020-09-08

snf701207 (审核中...)

前往app查看评论内容

#mAb#

ASCO 2020：罗氏的TIGIT单抗tiragolumab与PD-L1单抗Tecentriq联合，延长了非小细胞肺癌患者生存期

2021-03-19

snf701207 (审核中...)

前往app查看评论内容

#mAb#

FDA批准治疗银屑病关节炎的**种白介素-23单抗TREMFYA（guselkumab）

2020-10-24

snf701207 (审核中...)

前往app查看评论内容

#mAb#

欧盟监管机构开始审查LEO的IL-13单抗tralokinumab，治疗特应性皮炎

2021-04-22

科室
- - 订阅+
  - 更多科室
工具
服务